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Scaring Myocardial Scars
New Targets for the Electrical Fairy?*
Nathan Mewton, MD, PHD,†
Philippe Chevalier, MD, PHD‡
Lyon, France
Despite the impressive development of medical therapies for
patients with myocardial dysfunction, sudden cardiac death
(SCD) is still too frequent. In patients with severe cardio-
myopathies the insertion of an implantable cardiac defibril-
lator (ICD) has been shown to reduce SCD risk (1). For
primary prevention in patients with left ventricular ejection
fraction (LVEF) below 35%, ICD is now recommended (2).
However, only 30% to 50% of implanted patients received
appropriate ICD firings, and up to 25% suffered from side
effects in the first year after ICD insertion (3,4). In addition,
because of steadily growing demand for ICD replacements
(5), the financial burden of primary ICD insertion on our
healthcare systems is increasing. Consequently, there is an
urgent need to improve the benefit-risk ratio of ICD
insertion.
See page 408
The assessment of myocardial scarring with delayed
enhanced cardiac magnetic resonance (DE-CMR) has be-
come an important and independent prognostic factor of
cardiovascular outcomes in various cardiomyopathies (6). It
is now established that myocardial scar and/or its correlates
(scar pattern, relative size, heterogenous scar periphery size,
transmurality) by DE-CMR are independent prognostic
markers of cardiac death or ventricular tachycardia (VT)
occurrence in patients with ischemic (7–12), nonischemic
(13,14), and hypertrophic cardiomyopathies (15,16) as well
as in patients referred for ICD insertion (8,17). Simple
myocardial scar assessment by DE-CMR is an accurate,
reproducible, and reliable tool when put in trained hands.
Therefore it could be reasonably integrated in addition to the
precise measurement of LVEF by cardiac magnetic resonance
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therapeutic management of candidates for ICD insertion.
With this in mind, the original article by Klem et al. (18) in
this issue of the Journal is a cornerstone for the constitution
of clinical trials integrating myocardial scar assessment by
DE-CMR in the decision for ICD insertion.
In a prospective single-center cohort study on 137 pa-
tients referred for ICD insertion, Klem et al. (18) performed
an expert and simple cardiac MRI study assessing myocar-
dial scar and LVEF before implantation. The mean LVEF
was 35  18%, and 75% (n  104) of the patients had an
CD placed, with an indication of primary prevention in
8%. Of the entire patient population, 78% (n  107) had
car by DE-CMR, while at the same time 76% (n  105)
nderwent an electrophysiology study with VT induction in
0% (n  21).
At 24 months, the primary endpoint occurred in 28%
n  39) of the patients with an approximately equal
istribution of events between death and ICD discharge.
mportantly, there were no patients lost to follow-up. The
triking finding in this study is that there was a 5-fold
ncrease in the rate of adverse events for a scar size 5% of
he left ventricular (LV) mass and that scar size dichoto-
ized approximately 5% of the LV mass provided a signif-
cant increment in prognostic value in addition to that of
VEF as assessed by integrated discrimination improve-
ent and net reclassification improvement.
This work confirms and adds important information to
rior reports in similar settings (8,17). However, it still does
ot provide any evidence on the value of LV scar assessment
o help the physician decide whether a patient needs an
CD. To solve this question, prospective interventional
rials in larger cohorts of patients will have to be built on the
elatively solid ground set by the investigations of Klem et
l. (18) and previous reports.
In addition to the relatively limited sample size and the
ingle-center setting, other limits are that the investigators
eported a relatively modest predictive value on SCD and
CD discharge of scar analyzed as a continuous variable
hazard ratio: 1.04, 95% confidence interval: 1.00 to 1.07,
 0.03). Except for an electrophysiological study in a large
ub-group, no other electrophysiological variables were
ssessed (T-wave alternans, QT variability, signal averaged
lectrocardiogram, spatial QRS-T angle). Also, myocardial
carring or fibrosis can be caused by different mechanisms
ccording to the underlying cardiomyopathy. Therefore
here could be different types of fibrosis that could have a
ifferent arrhythmogenic impact. The mechanisms by
hich myocardial scars facilitate ventricular arrhythmias are
ot completely understood. It is accepted that the scarred
issue creates regions of slowed or incomplete electrical
onduction that favor macro-reentrant circuits and, in turn,
T (9). By contrast, the underlying mechanisms that yieldo ventricular fibrillation are less clear.
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abnormality but of a group of factors that together lead to
the fatal event. Consequently, the predictive values of single
variables are not discriminant enough for arrhythmogenic
profiling. New methods incorporating different parameters
are needed to characterize ventricular electrical instability.
Neuroimaging, genotyping, and quantitative analysis of
ventricular repolarization with Holter recordings are prom-
ising (19–22). The work of Klem et al. shows that an
accurate measurement of fibrosis by DE-CMR could be
added to the list of noninvasive markers that will help to
better risk-stratify patients with abnormal LVEF.
In the field of sudden death prediction, the complexity of
arrhythmogenesis makes it necessary to take several param-
eters into account. The work of Klem et al. is a step toward
a better selection of candidates for ICD insertion and also
stresses the need for a multimodal approach to assess
ventricular arrhythmia risk. The combination of data from
cross-sectional imaging, neuroimaging, genotyping, and
Holter analysis should make it possible to establish risk
scores, increasing the relevance of ICD insertion.
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